GOOD NEWS !!!
Matritech and Curtin Matheson Scientific/Fisher HealthCare Sign Distribution Agreement for
Bladder Cancer Test
PR Newswire, Thursday, March 19, 1998 at 08:46
NEWTON, Mass., March 19 /PRNewswire/ -- Matritech, Inc. (NASDAQ:NMPS) and
Curtin Matheson Scientific (CMS) / Fisher HealthCare, a division of Fisher
Scientific International Inc., announced today that the two companies have
signed an agreement for CMS to distribute the Matritech NMP22(R) Test Kit for
the management of bladder cancer patients, in the United States. CMS/Fisher
HealthCare is a leader in the distribution of diagnostic products to clinical
laboratories.
"Based on the impressive clinical results of the test, we have selected
NMP22 as our sole product for the management of bladder cancer patients. We
believe that this product has the potential to bring significant value to a
large patient population," said Jack Daniels, Vice President of Marketing for
CMS/Fisher HealthCare. "CMS/Fisher HealthCare maintains a strong position in
providing diagnostic products to the laboratory community, and we see NMP22 as
a key addition to our current product portfolio."
"CMS/Fisher HealthCare is a major distributor of diagnostic products with
a strong business in hospital and clinical laboratories nationwide and a 170-
person sales force," said David L. Corbet, President of Matritech. "Expanding
our U.S. distribution is a key piece of Matritech's overall strategy for
promoting the NMP22 Test Kit. We are also focused on continuing to target key
thought leaders in the field and securing partners for automated testing
systems."
Matritech, Inc. based in Newton, Massachusetts, is using its proprietary
nuclear matrix protein (NMP) technology, discovered at the Massachusetts
Institute of Technology (MIT) and licensed exclusively to Matritech, to
develop and commercialize innovative serum-, cell- and urine-based NMP
diagnostics that enable physicians to reliably detect and monitor the presence
of bladder, colon, cervical, breast and prostate cancers.
Fisher Scientific is the world leader in serving science, providing more
than 245,000 products and services to research, healthcare, industrial,
educational and government customers in 145 countries.
Except for historical information contained herein, the matters discussed
in this news release are forward-looking statements that are subject to risks
and uncertainties. Potential risks and uncertainties include, without
limitation, potential fluctuations in the Company's sales due to the timing of
customer orders and other market conditions beyond the Company's control, and
risks related to the Company's ability to: successfully develop, test,
produce, and market its products; obtain necessary government approvals in a
timely manner; attract and keep key employees; raise capital for future
operations and growth; and successfully respond to technological changes in
the marketplace. Additional information on potential factors which could
affect the Company's financial results are included in the Company's public
filings with the Securities and Exchange Commission.
SOURCE Matritech, Inc.
-0- 03/19/98
/CONTACT: Stephen D. Chubb, CEO, or David L. Corbet, President of
Matritech, Inc., 617-928-0820 or Paul Descheneaux of Director of Marketing of
CMS, 281-878-3569 or Derek Caldwell of Sunrise Financial Group, 212-421-1616
or Robert Gottlieb or Gretchen L.P. Schweitzer of Feinstein Kean Partners,
617-577-8110/
Companies or Securities discussed in this article:
Symbol
Name
NASDAQ:NMPS
Matritech Inc |
